Fig. 6. KVax synergizes with CA170 treatment to increase antitumor effector CD4⁺ T cells response and to decrease Treg-mediated immunosuppression in the tumor.

A UMAP plot showing cellular heterogeneity of CD4⁺ T cells from two CD45⁺ scRNA-seq datasets and CD3⁺scRNA-seq datasets. Each dot represents a single cell and is colored according to corresponding CD4 subset. B Representative genes for naïve (Ccr7), Effector Th1 and T_FH (Cxcr6 and Cxcr5, respectively) and Treg (Foxp3) specific genes shown across all clusters using the feature plot. C Heatmap showing average expression of different CD4⁺ Naïve and Effector memory T cell-specific genes (Naïve-Eff-Mem), CD4 Effector T cell-specific genes and Treg-specific genes across all cells in all clusters for the five lung cancer treatments. D Bar plot showing the percentage of different CD4 T cell clusters for the five treatment conditions individually. E Percentage of naïve, effector, and suppressor (Treg) cells across four CD4⁺ T cell samples for the five different lung cancer treatments. F Ratio of CD4 Effector vs Suppressor cells across four CD4⁺ T cell samples for the five different lung cancer treatments. Data are shown as the mean ± SE, n = 4, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 vs Ctrl.